DUBLIN , Sept. 8, 2022 /PRNewswire/ -- The "Tissue Diagnostic Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
The global tissue diagnostic market is expected to grow from $4.27 billion in 2021 to $4.56 billion in 2022 at a compound annual growth rate (CAGR) of 6.84%. The tissue diagnostic market is expected to grow to $5.99 billion in 2026 at a compound annual growth rate (CAGR) of 7.05%.
The tissue diagnostic market consists of sales of tissue diagnostics devices by entities (organizations, sole traders, and partnerships) that refer to a medical procedure that uses instruments to remove and stain tissue that must be sent to a laboratory or pathology department for documentation of what was excised for patient care (for tissue diagnostics). This offers measurements and descriptions including any abnormalities, and an interpretation (or diagnosis) of health or disease status, under applicable legislation.
The main types of product in tissue diagnostic are consumables, antibodies, kits, reagents, probes, instrument, slide staining system, scanner and tissue processing system. The antibodies are used for the detection of infections, recognition of allergies, and the measurement of hormones and other biological markers in the blood in tissue diagnostics.
The technologies used in tissue diagnostic are immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology and workflow management and special staining to detect diseases such as breast cancer, gastric cancer, lymphoma, prostate cancer and non-small cell lung cancer (NSCLC). Tissue diagnostic is mostly used in hospitals, research laboratories, pharmaceutical companies and contract research organizations.
North America was the largest region in the tissue diagnostic market in 2021. The regions covered in the tissue diagnostic market report are Asia-Pacific , Western Europe , Eastern Europe , North America , South America , Middle East and Africa .
The rising incidence of cancer will propel the growth of the tissue diagnostics market during the forecast period. Cancer begins when genetic changes interfere, and cells start to grow uncontrollably and destroy body tissue and form a mass called a tumor. A tumor can be cancerous or benign.
Cancer can be caused due to various reasons such as genetic mutations, cancer-causing chemicals (carcinogens), smoking, obesity, radiation, hormones and others. As the instances of occurring cancer increase, there will be a significant need for diagnostic procedures such as tissue diagnostics help in determining the disease state.
For instance, according to the US voluntary health organization dedicated to eliminating cancer, the American Cancer Society, in the USA , there was an expected 1.8 million new cancer cases identified and 606,520 cancer deaths in 2020, and the number was expected to increase to 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in 2021. Therefore, the rising incidence of cancer drives the tissue diagnostics market.
Technological advancement is a key trend gaining popularity in the tissue diagnostics market. Technological advancements include the introduction of automated tissue diagnostic devices/machines that collect multiple sample types, test multiple samples simultaneously, automate lab operations, and make it accessible to everyone.
Key players are focused on developing and offering these automated tissue diagnostic systems to gain a competitive edge in the market and increase revenue. For instance, in July 2020 , Mylab Discovery Solutions, an Indian molecular diagnostics company introduced Compact XL - Lab in a Box, India's first fully automated Sample-to-PCR-ready system for molecular diagnostics.
The new system automates lab operations from sample handling to RT-PCR ready tube preparation and does these operations in one single compact benchtop system. The system can collect various types of samples such as tissue, plasma, swab, and sputum.
In February 2022 , Labcorp, a US-based global life sciences company acquired Personal Genome Diagnostics (PGDx) for an amount of $575 million . With the addition of PGDx and its technology, Labcorp will expand its next-generation sequencing-based genomic profiling capabilities and strengthens the existing liquid biopsy capabilities. Personal Genome Diagnostics (PGDx) is an US-based company offering cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products.
The countries covered in the tissue diagnostic market report are Australia , Brazil , China , France , Germany , India , Indonesia , Japan , Russia , South Korea , UK and USA .
Major players in the tissue diagnostic market are
Key Topics Covered: 1. Executive Summary 2. Tissue Diagnostic Market Characteristics 3. Tissue Diagnostic Market Trends And Strategies 4. Impact Of COVID-19 On Tissue Diagnostic 5. Tissue Diagnostic Market Size And Growth 5.1. Global Tissue Diagnostic Historic Market, 2016-2021, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Tissue Diagnostic Forecast Market, 2021-2026F, 2031F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Tissue Diagnostic Market Segmentation 6.1. Global Tissue Diagnostic Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
6.2. Global Tissue Diagnostic Market, Segmentation By Technology, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Digital Pathology And Workflow Management
6.3. Global Tissue Diagnostic Market, Segmentation By Disease, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
Non-Small Cell Lung Cancer (NSCLC)
6.4. Global Tissue Diagnostic Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7. Tissue Diagnostic Market Regional And Country Analysis 7.1. Global Tissue Diagnostic Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion 7.2. Global Tissue Diagnostic Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/sz2yg3
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-tissue-diagnostic-market-report-2022-2026--2031-focus-on-immunohistochemistry-ihc-in-situ-hybridization-ish-digital-pathology-and-workflow-management--special-staining-301620700.html
The FDA is convening an adcomm meeting of its Pulmonary-Allergy Drugs Advisory Committee, slated for October 6, to discuss Veru Inc's (NASDAQ: VERU) request for Emergency Use Authorization of sabizabulin for hospitalized COVID-19 patients at high risk for ARDS. In a public notice, the FDA said that as part of the adcomm, one of the focuses of the experts will include "the treatment effect size in the context of the high placebo mortality rate, the limited size of the safety database, and identif
Nursing homes and debt collectors are billing and suing long-term-care residents’ family members and friends, demanding payments for debts these individuals don’t legally owe, consumer attorneys and federal regulators are claiming. Under federal law, nursing homes participating in Medicare and Medicaid can’t make such provisions a condition of admission or continued stay in the facility.
A few months ago, I started buying stock in Intel, betting that the company would become a monopoly chip manufacturer outside Asia. Whether you know it or not, you’re betting on Intel too. The largest and most advanced companies in the U.S., and even our military superiority, depend on access to the most advanced semiconductor chips in the world.
Rivian Automotive is seeing more active turnover (volume) Friday as traders may be encouraged by the company's announcement of a hook-up with Mercedes-Benz . Let's check out the charts and indicators.
Zscaler gapped higher Friday in reaction to a better than expected Q4 report and guidance. Let's check out the charts of this cybersecurity firm. In this daily bar chart of ZS, below, we can see that prices opened sharply higher Friday.
Shares of Tesla (NASDAQ: TSLA) rose 3.6% on Friday following reports that the electric vehicle (EV) maker is considering making a big move into the lithium industry. The tech-heavy NASDAQ was up by 2.1% for the day. Elon Musk has repeatedly urged entrepreneurs to get into the lithium refining business as the price of the metal has surged.
Tesla Inc. is proposing to build a lithium refinery in Texas, adding to its presence in the state and following the advice of its own Chief Executive Elon Musk a few months ago.
Exelixis Inc (NASDAQ: EXEL) announced detailed results from the COSMIC-313 Phase 3 trial cabozantinib (Cabometyx), nivolumab, and ipilimumab combo in untreated advanced renal cell carcinoma (RCC) patients. The data are being presented at the 2022 European Society of Medical Oncology (ESMO) Congress. As previously announced, the cabozantinib combination significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab. The cabozantinib combin
Studies "support aflibercept 8 mg as a potential new standard-of-care," Regeneron Pharmaceuticals said. Regeneron stock leapt in huge volume.
When planning for the future, health care ranks as one of the highest concerns for both savers and retirees alike. Not only are health care costs rising by more than 5% every year, but rampant inflation and volatile market performances … Continue reading → The post New Bill May Allow Penalty-Free 401(k) Withdrawals for This Retirement Expense appeared first on SmartAsset Blog.
Expect cost certainty to fly right out the (drafty) window.
Regeneron's Eylea eye-disorder drug faces competitive pressure on multiple fronts. New data could cement its dominance.
Revance CEO Mark Foley joins Yahoo Finance Live to discuss the therapeutic company's anti-wrinkle Daxxify treatment, its multi-use purposes, and its competition with traditional Botox injections.
Yahoo Finance reporter Jen Schonberger details an upcoming Treasury report that will highlight the economic danger of cryptocurrency.
Amylyx Pharmaceuticals Inc. shares were riding high in the first few hours of trading following a key FDA advisory committee's positive vote on its first drug, despite the unusual caveats that accompanied the vote.
Jefferies upgrades the stock and other analysts raise their price targets on Regeneron following better-than-expected data on a new formulation of the company's signature eye medication.
Tesla stock is climbing today in midday trade, up over 2% and up nearly 10% for the week. Here are two big stories driving shares today.
FDA approves AstraZeneca's (AZN) Imfinzi combination for advanced metastatic biliary tract cancer and grants Breakthrough Therapy Designation to Pfizer's (PFE) Group B Streptococcus (GBS) vaccine.
These strategies can help you reduce your health care costs.
Axios Media Reporter Sara Fischer joins Yahoo Finance Live to discuss the latest in streaming wars and why price consolidation may be necessary.